Free Newsletter
Opportunity knocks for software makers


OK, software makers, you're up.
Drug developers need capacity-planning solutions--really good ones that account for resource costs (see related story). And they have to be up to the challenges of increasingly complex clinical trial protocols, including those for adaptive trials, and accurate enough to show cost savings.
Yes, you've provided clinical capacity-planning features within trial management solutions. But now it's time to step it up a notch, says Kenneth Kaitin of the Tufts Center for the Study of Drug Development.
The need is now for capacity-planning solutions based on an accurate understanding of resource costs. Here's your chance to shine.
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: